SEARCH

SEARCH BY CITATION

References

  • 1
    Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15(9):61827.
  • 2
    Sanford K. Findings and Recommendations of the Task Force to Prevent Deaths from Unintentional Drug Overdoses in North Carolina, 2003. N.C. Injury and Violence Prevention Branch—North Carolina Department of Health and Human Services, Editor; 2004. Available at: http://www.ncpublichealth.com (accessed December 2008).
  • 3
    Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35(4):50116.
  • 4
    Isbell H, Wikler A. Tolerance and addiction liability of 6-dimethylamino-4-4-diphenylheptanone-3 (methadon). J Am Med Assoc 1947;135(14):88894.
  • 5
    Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007;90(1):6471.
  • 6
    Inciardi J, Surratt H, Lugo Y, Cicero T. The diversion of prescription opioid analgesics. Law Enforc Exec Forum 2007;7(7):12741.
  • 7
    Drug Enforcement Agency. Schedules of controlled substances: Rescheduling of buprenorphine from schedule V to schedule III. Fed Regist 2002;67(194):6235470.
  • 8
    Food and Drug Administration. FDA Public Health Advisory, Methadone Use for Pain Control May Result in Death and Life-Threatening Changes in Breathing and Heart Beat. Bethesda, MD: Center for Drug Evaluation and Research; 2007.
  • 9
    Drug Enforcement Agency. Methadone Hydrochloride Tablets USP 40 mg (Dispersible). Available at: http://www.deadiversion.usdoj.gov/pubs/pressrel/methadone_advisory.htm 2007 (accessed March 2009).
  • 10
    Blackwell SA, Montgomery MA, Waldo D, et al. National study of medications associated with injury in elderly Medicare/Medicaid dual enrollees during 2003. J Am Pharm Assoc 2003,2009;49(6):7519.
  • 11
    Bunn TL, Yu L, Spiller HA, Singleton M. Surveillance of methadone-related poisonings in Kentucky using multiple data sources. Pharmacoepidemiol Drug Saf 2010;19(2):12431.
  • 12
    Graham NA, Merlo LJ, Goldberger BA, Gold MS. Methadone- and heroin-related deaths in Florida. Am J Drug Alcohol Abuse 2008;34(3):34753.
  • 13
    Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300(22):261320.
  • 14
    Sanford CP. An Unrelenting Epidemic of Deaths from Prescription Drugs in North Carolina. Forum (North Carolina Medical Board) 2008;2:47.
  • 15
    Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict 2009;18(1):514.
  • 16
    Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 152(2):8592.
  • 17
    Andrews CM, Krantz MJ, Wedam EF, et al. Methadone-induced mortality in the treatment of chronic pain: Role of QT prolongation. Cardiol J 2009;16(3):2107.
  • 18
    Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005;14(11):74753.
  • 19
    Wilford B, Maxwell J. Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators. Available at: http://buprenorphine.samhsa.gov/Buprenorphine_FinalReport_12.6.06.pdf 2006 (accessed March 2009).
  • 20
    Clark W. Buprenorphine in the treatment of opioid addiction: Balancing medication access with quality care. Paper presented at: SAMSHA Conference; 2008; Washington, DC.
  • 21
    Dasgupta N, Kramer ED, Zalman MA, et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006;82(2):13542.
  • 22
    Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage 2004;28(2):17688.
  • 23
    Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: A revisit. Pain Med 2004;5(1):5965.
  • 24
    Williams RE, Sampson TJ, Kalilani L, Wurzelmann JI, Janning SW. Epidemiology of opioid pharmacy claims in the United States. J Opioid Manag 2008;4(3):14552.
  • 25
    Zerzan JT, Morden NE, Soumerai S, et al. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care 2006;44(11):100510.
  • 26
    Shaiova L. The role of methadone in the treatment of moderate to severe cancer pain. Support Cancer Ther 2005;2(3):17680.
  • 27
    Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002209.
  • 28
    Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD002207.
  • 29
    Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: The international experience. Clin Infect Dis 2006;43(Suppl 4):S197215.
  • 30
    Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction 2005;100(11):1690700.
  • 31
    Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001;285(1):45.
  • 32
    Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend 2009;105(1–2):915.
  • 33
    Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009;104(7):1193200.
  • 34
    Marzo JN, Rotily M, Meroueh F, et al. Maintenance therapy and 3-year outcome of opioid-dependent prisoners: A prospective study in France (2003–06). Addiction 2009;104(7):123340.
  • 35
    Gibson A, Degenhardt LJ. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008;103(3):4628.
  • 36
    Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: A comparative analysis of coronial records. Drug Alcohol Rev 2007;26(4):40510.
  • 37
    Soyka M, Apelt SM, Lieb M, Wittchen HU. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: A nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006;26(6):65760.
  • 38
    Soyka M, Penning R, Wittchen U. Fatal poisoning in methadone and buprenorphine treated patients—Are there differences? Pharmacopsychiatry 2006;39(3):857.
  • 39
    Nielsen S, Dietze P, Cantwell K, Lee N, Taylor D. Methadone- and buprenorphine-related ambulance attendances: A population-based indicator of adverse events. J Subst Abuse Treat 2008;35(4):45761.
  • 40
    Boyd J, Randell T, Luurila H, Kuisma M. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003;47(8):10313.
  • 41
    Lai SH, Yao YJ, Lo DS. A survey of buprenorphine related deaths in Singapore. Forensic Sci Int 2006;162(1–3):806.
  • 42
    Megarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression?: Possible mechanisms and therapeutic consequences. Toxicol Rev 2006;25(2):7985.
  • 43
    Pirnay S, Borron SW, Giudicelli CP, et al. A critical review of the causes of death among post-mortem toxicological investigations: Analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004;99(8):97888.
  • 44
    Schifano F, Corkery J, Gilvarry E, et al. Buprenorphine mortality, seizures and prescription data in the UK, 1980–2002. Hum Psychopharmacol 2005;20(5):3438.
  • 45
    Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. J Anal Toxicol 1998;22(6):4304.
  • 46
    Cicero TJ, Dart RC, Inciardi JA, et al. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med 2007;8(2):15770.
  • 47
    Inciardi JA, Cicero TJ, Munoz A, et al. The diversion of ultram, ultracet, and generic tramadol HCL. J Addict Dis 2006;25(2):538.
  • 48
    Cicero TJ, Inciardi JA, Adams EH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994–2004. Pharmacoepidemiol Drug Saf 2005;14(12):8519.
  • 49
    Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002–2004. J Pain 2005;6(10):66272.
  • 50
    Cicero TJ, Surratt H, Inciardi JA, Munoz A, et al. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007;16(8):82740.
  • 51
    American Association of Poison Control Centers National Poison Data System (NPDS). NPDS Reference Manual. 2007.
  • 52
    Watson WA, Litovitz TL, Belson MG, et al. The Toxic Exposure Surveillance System (TESS): risk assessment and real-time toxicovigilance across United States poison centers. Toxicol Appl Pharmacol 2005;207(2 Suppl):60410.
  • 53
    Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: A pilot study and descriptive comparison. Clin Toxicol (Phila) 2007;45(2):14451.
  • 54
    Smith MY, Dart R, Hughes A, et al. Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids. Am J Drug Alcohol Abuse 2006;32(3):46578.
  • 55
    Bailey JE, Barton PL, Lezotte D, Lowenstein SR, Dart RC. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Drug Alcohol Depend 2006;84(2):1827.
  • 56
    Smith MY, Schneider MF, Wentz A, et al. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: A comparison of two approaches. Clin Toxicol (Phila) 2007;45(1):2330.
  • 57
    Department of Health and Human Services. Certification of opioid treatment programs, in 42 CFR, Section 8. G.P. Office, Editor. 2002.
  • 58
    Department of Justice. Drug abuse prevention and control, in 21 CFR, Chapter 13, D.E. Agency, Editor.
  • 59
    Drug Addiction Treatment Act of 2000. XXXV—Waiver Authority for Physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment, in Public Law 106-310. 2000.
  • 60
    Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Department of Health and Human Services; 2006.
  • 61
    Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Department of Health and Human Services; 2008.
  • 62
    Roche A, McCabe S, Smyth BP. Illicit methadone use and abuse in young people accessing treatment for opiate dependence. Eur Addict Res 2008;14(4):21925.
  • 63
    Vlahov D, O'Driscoll P, Mehta SH, et al. Risk factors for methadone outside treatment programs: Implications for HIV treatment among injection drug users. Addiction 2007;102(5):7717.
  • 64
    Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend 2008;92(1–3):26776.
  • 65
    Ridge G, Gossop M, Lintzeris N, Witton J, Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abuse Treat 2009;37(1):95100.
  • 66
    Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag 2007;3(6):3028.
  • 67
    Wittchen HU, Apelt SM, Soyka M, et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients. Drug Alcohol Depend 2008;95(3):24557.
  • 68
    Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug Alcohol Depend 2008;94(1–3):1517.
  • 69
    Darke S, Ross J, Teesson M. The Australian Treatment Outcome Study (ATOS): What have we learnt about treatment for heroin dependence? Drug Alcohol Rev 2007;26(1):4954.
  • 70
    Peles E, Schreiber S, Adelson M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend 107(2–3):1418.
  • 71
    Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007;102(12):19549.
  • 72
    Deck D, Wiitala W, McFarland B, et al. Medicaid coverage, methadone maintenance, and felony arrests: Outcomes of opiate treatment in two states. J Addict Dis 2009;28(2):89102.
  • 73
    Steentoft A, Teige B, Holmgren P, et al. Fatal poisoning in Nordic drug addicts in 2002. Forensic Sci Int 2006;160(2–3):14856.
  • 74
    Bailey JE, Campagna E, Dart RC. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med 2009;53(4):41924.
  • 75
    Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. Pediatrics 2008;121(4):e7826.
  • 76
    Letsky MC, Zumwalt RE, Seifert SA, Benson BE. Cause of death conundrum with methadone use: A case report. Am J Forensic Med Pathol 2010 (in press).
  • 77
    Kintz P, Evans J, Villain M, Cirimele V. Interpretation of hair findings in children after methadone poisoning. Forensic Sci Int 2010;196(1–3):514.
  • 78
    Chugh SS, Socoteanu C, Reinier K, et al. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008;121(1):6671.
  • 79
    Eissenberg T, Greenwald MK, Johnson RE, et al. Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 1996;276(2):44959.
  • 80
    Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009;35(2):6872.
  • 81
    Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology (Berl) 2005;181(4):66475.
  • 82
    Vormfelde SV, Poser W. Death attributed to methadone. Pharmacopsychiatry 2001;34(6):21722.
  • 83
    Deck DD, Wiitala WL, Laws KE. Medicaid coverage and access to publicly funded opiate treatment. J Behav Health Serv Res 2006;33(3):32434.